The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to
evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced
delayed nausea and vomiting (CINV) in chemotherapy-naive patients after multi-cycle
cisplatin-containing highly emetogenic chemotherapy (HEC) .